SEARCH

SEARCH BY CITATION

References

  • 1
    Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004; 171: 1141-1147.
  • 2
    Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439.
  • 3
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000; 355: 1491-1498.
  • 4
    Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997; 50: 330-336.
  • 5
    Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology. 2004; 4: 5-13.
  • 6
    Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004; 93: 1177-1182.
  • 7
    Rothmann M, Li N, Chen G, et al. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. 2003; 22: 239-264.
  • 8
    Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004; 34: 20-28.
  • 9
    Usami M, Akaza H, Arai Y, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007; 10: 194-201.
  • 10
    Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007; 25: 1596-1605.
  • 11
    Akaza H, Arai Y, Kanetake H, et al. Efficacy of combined androgen blockade (CAB) therapy in stage C prostate cancer: exploratory analyses based on results of a double-blind, randomized, placebo-controlled phase III study of bicalutamide, 07 update. Available at: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Virtual+Meeting?&vmview= vm_session_presentations_view&confID=47&sessionID=358. Accessed on June 5, 2009.
  • 12
    Japanese Urological Association and the Japanese Society of Pathology. General rule for clinical and pathological studies on prostatic cancer. 2nd edition. Tokyo: Kanehara. 1992.
  • 13
    Kotake T, Usami M, Isaka S, et al. [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer]. Hinyokika Kiyo. 1996; 42: 157-168.
  • 14
    Kotake T, Akaza H, Usami M. Preliminary trial for clinical phase III study of Casodex-combination therapy with LH-RH agonist for prostate cancer. J N Remed Clin. 1999; 48: 1512-1533.
  • 15
    Akaza H. Current status and prospects of androgen depletion therapy for prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008; 22: 293-302.
  • 16
    Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur Urol. 1998; 33: 134143.
  • 17
    Kwak C, Jeong SJ, Park MS, et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol. 2002; 168: 995-1000.
  • 18
    Altwein JE, Schmidt A. Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration. Urol Int. 2002; 68: 220-225.
  • 19
    Lukka H, Waldron T, Klotz L, et al. Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review. Curr Oncol. 2006; 13: 81-93.
  • 20
    Hinotsu A, Niimi M, Akaza H, et al. [Development of Japanese version of QOL questionnaire for bladder and prostate cancer patients using FACT-Bl and P: pilot study]. Gan To Kagaku Ryoho. 1999; 26: 657-666.
  • 21
    Arai Y, Akaza H, Deguchi T, et al. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol. 2008; 134: 1385-1396.
  • 22
    Nishimura S, Arai Y, Usami M, et al. [Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer]. Gan To Kagaku Ryoho. 2007; 34: 589-595.
  • 23
    Ramsey S, Veenstra D, Clarke L, et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology. 2005; 66: 835-839.
  • 24
    Penson DF, Ramsey S, Veenstra D, et al. The cost-effectiveness of combined androgen blockade with bicalutamide and LHRH agonist in men with metastatic prostate cancer. J Urol. 2005; 174: 547-552.